


PHARMACEUTICAL 2017



AGIOS PHARMACEUTICALS INC. Rank 54 of 292





PHARMACEUTICAL 2017





AGIOS PHARMACEUTICALS INC. Rank 54 of 292

The relative strengths and weaknesses of AGIOS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGIOS PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of AGIOS PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 202%, being 199% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	559,892
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	88,433
Liabilities, Non-Current	0
Other Assets	33,865
Other Compr. Net Income	5.0
Other Expenses	0
Other Liabilities	0
Other Net Income	2,514
Other Revenues	69,892
Property and Equipment	25,337
Research and Development	220,163
Selling, General and Administrative Expense	50,714

Output Variable	Value in 1000 USD
Assets	619,094
Liabilities	88,433
Expenses	270,877
Revenues	69,892
Stockholders Equity	530,661
Net Income	-198,471
Comprehensive Net Income	-198,468
Economic Capital Ratio	202%